Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Ugandan authorities launched a clinical trial of a vaccine against the Sudan strain of Ebola that has killed one nurse in the ...

H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...

The Vaccine and Infectious Disease Organization out of the University of Saskatchewan has received a $24 million grant to aid ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Nearly two years into the COVID-19 pandemic, Canada is ramping up its vaccine program in an effort to deliver booster doses to eligible Canadians. A booster shot is an additional dose of a COVID ...

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...

Robert F. Kennedy's nomination will put Republican lawmakers' loyalty to the test, as the former Democrat holds a range of ...

TORONTO - Health Canada has received more units of the rabies vaccine and expects they will be distributed by the end of the month as Toronto continues to ration its doses amid a shortage. An increase ...

TORONTO - Health Canada has received more units of the rabies vaccine and expects they will be distributed by the end of the month as Toronto continues to ration its doses amid a shortage.